Kineta Board Member's Stock Moves Signal Confidence During TuHURA Merger
Rhea-AI Filing Summary
Kineta Director Kimberlee C. Drapkin reported multiple securities transactions on Form 4, detailing changes in beneficial ownership on June 23-25, 2025:
- Exercised 12,500 stock options at $0.611 per share on June 23
- Disposed of 4,706 common shares at $0.26 per share through tax withholding (Form F)
- Received 6,000 new shares as an award on June 25 at $0 cost
The transactions were executed following the approval of a merger agreement between Kineta and TuHURA Biosciences at a Special Meeting of Stockholders on June 23, 2025. Per the Optionholder Treatment Agreement dated June 16, 2025, and merger agreement dated December 11, 2024 (amended May 5, 2025), the reporting person's options under the 2022 Equity Incentive Plan became fully vested. Following all transactions, Drapkin directly owns 13,794 common shares with no remaining stock options.
Positive
- Director received 6,000 shares as new stock grant, demonstrating continued alignment with shareholder interests
Negative
- None.
Insider Trade Summary
Net Buyer: 13,794 shares
Net Buy
4 txns
Insider
Drapkin Kimberlee C
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock | 6,000 | $0.00 | $0.00 |
| Exercise | Stock Option (Right to Buy) | 12,500 | $0.00 | $0.00 |
| Exercise | Common Stock | 12,500 | $0.611 | $8K |
| Exercise Price or Tax Liability | Common Stock | 4,706 | $0.26 | $1K |
Holdings After Transaction:
Stock Option (Right to Buy) — 0 shares (Direct);
Common Stock — 13,794 shares (Direct)
Footnotes (1)
- F1. Pursuant to the terms of (i) the Optionholder Treatment Agreement, dated June 16, 2025, by and between Kineta, Inc. (the "Company") and the Reporting Person, and (ii) the Agreement and Plan of Merger, dated as of December 11, 2024, by and among the Company, TuHURA Biosciences, Inc., a Nevada corporation ("TuHURA"), Hura Merger Sub I, Inc., a Delaware corporation and a wholly owned subsidiary of TuHURA, Hura Merger Sub II, a Delaware limited liability company and a wholly owned subsidiary of TuHURA, and Craig Philips, as representative of the stockholders of the Company, and as amended by that certain First Amendment to Agreement and Plan of Merger, dated May 5, 2025, as approved by the Company's stockholders at the Special Meeting of Stockholders held on June 23, 2025, the options granted to the Reporting Person under the 2022 Equity Incentive Plan became fully vested on June 23, 2025.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What insider transactions did Kimberlee Drapkin make in KA stock on June 23, 2025?
On June 23, 2025, Kimberlee Drapkin exercised 12,500 stock options at $0.611 per share (acquired) and subsequently had 4,706 shares withheld for taxes (disposed) at $0.26 per share. After these transactions, she held 7,794 shares directly.
What was the exercise price of KA stock options that Drapkin exercised?
Kimberlee Drapkin exercised stock options with an exercise price of $0.611 per share. These options were originally set to expire on September 3, 2034, but were exercised early on June 23, 2025.
Why did KA director Kimberlee Drapkin's stock options vest early?
The options vested early on June 23, 2025, pursuant to an Optionholder Treatment Agreement dated June 16, 2025, and a merger agreement between Kineta and TuHURA Biosciences. This early vesting was approved by stockholders at a Special Meeting held on June 23, 2025.